| Therapeutic modality |
Mode of action and Remarks |
| Glucocorticoids |
Increase hepatic gluconeogenesis and peripheral insulin resistance
Decrease insulin secretion and peripheral glucose utilization |
| Diazoxide, Streptozotocin |
Reduce insulin secretion by direct beta cell toxicity |
| Somatostatin analogues |
Actions mediated through somatostatin receptors
Not as effective in malignant compared to benign tumours |
| Interferon |
Induces cytotoxic lymphocyte mediated beta cell damage |
| Evorolimus (mTOR inhibitor) |
? Inhibits insulin secretion
? Induces insulin resistance
? anti tumour growth effects |
| Sunitinib (Tyrosine kniase inhibitor) |
Inhibits vascualr endothelial growth factor and platelet drived growth factor receptors |
| Radionuclides [19] |
Used mainly in unresectable somatostatin receptor positive tumours |
